

Biological Response Modifiers Advisory Committee
Meeting #29
April 5-6, 2001

Attachment to Briefing Materials

Bibliography

Session I

1. Donahue, R.E., et al., *Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer*. J. Exp. Med., 1992. **176**: p. 1125-1135.
2. Zhang, J. and H.M. Temin, *Rate and mechanism of nonhomologous recombination during a single cycle of retroviral replication*. Science, 1993. **259**: p. 234-238.
3. Purcell, D.F.J., et al., *An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer*. Journal of Virology, 1996. **70**(2): p. 887-897.
4. Hutchins, B., et al., *Working toward an adenoviral vector testing standard*. Molecular Therapy, 2000. **2**(6):p.532-534.
5. Jensen, M., G. Tan, S. Forman, A.M. Wu, and A. Raubitschek. 1998. CD20 is a molecular target for scFvFc: receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancies. *Biol. Bone Marrow Transplant.* 4:75.
6. Jensen, M.C., P. Clarke, G. Tan, C. Wright, C.C. Wen, T.N. Clark, F.Y. Zhang, M.L. Slovak, A.M. Wu, S.J. Forman, and A. Raubitschek. 2000. Human T lymphocyte genetic modification with naked DNA. *Molecular Therapy* 1:49.
7. Büeler, H. 1999. Adeno-associated viral vectors for gene transfer and gene therapy. *Biol. Chem.* 380:613.
8. Grimm, D., A. Kern, K. Rittner, and J.A. Kleinschmidt. 1998. Novel tools for production and purification of recombinant adeno-associated virus vectors. *Human Gene Therapy* 9:2745.
9. Soneoka, Y., P.M. Cannon, E.E. Ramsdale, J.C. Griffiths, G. Romano, S.M. Kingsman, and A.J. Kingsman. 1995. A transient three-plasmid expression system for the production of high titer retroviral vectors. *Nucleic Acids Res.* 23:628.
10. Hutchins, B., Sajadi, N., Seaver, S., Shepard, A., Bauer, S.R., Simek, S., Carson, K., Aguilar-Cordova, E. 2000. Working toward an adenoviral vector testing standard. *Molecular Therapy*: 2:532-534.
11. Foster, C.B., Choi, E.H., and Chanock, S.J. 2000. Adenovirus and marrow transplantation in children. *Ped. Path Molec Med.* 19:97-114.

12. Baldwin, A., Kingman, H., Darville, M., Foot, A.B.M., Grier, D., Cornish, J.M., Goulden, N., Oakhill A., Pamphilon, D.H., Steward, C.G., and Marks, D.I. 2000. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. *Bone Marrow Transplantation* 26: 1333-1338.
13. Flomenberg, P., Gutierrez, E., Piaskowski, V., and Casper, J.T. 1997. Detection of adenovirus DNA in peripheral blood mononuclear cells by polymerase chain reaction assay. *J. Med Virol.* 51: 182-188.5.
14. Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy - 3/30/98. (<http://www.fda.gov/cber/guidelines.htm>)
16. FDA Gene Therapy Letter, March 6, 2000 (<http://www.fda.gov/cber/letter.htm>)

Session III

1. Zheng, C., et al., *Genomic integration and gene expression by a modified adenoviral vector*. Nature Biotechnology, 2000. **18**: p. 176-180.
2. Fenner, F., *Poxviruses*, in *Virology*, B.N. Fields, D.M. Knipe, and P.M. Howley, Editors. 1996, Lipincott-Raven: Philadelphia. p. 2673-2678.
3. Flomenberg, P., et al., *Detection of adenovirus DNA in peripheral blood mononuclear cells by polymerase chain reaction assay*. J. Med. Virol., 1997. **51**: p. 182-188.
4. Van Leewen, FE, et al., Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol, 2000, **18**: p. 487-497.

Session IV

1. Ravold, A., *Special Article. Fatal results from diphtheria antitoxin in St. Louis.*, J.A.M.A., 1901, Nov. 9:p.1260-1261.
2. Proposed Rule - Availability for disclosure and submission to FDA for public disclosure of certain data and information related to human gene therapy or xenotransplantation. (<http://www.fda.gov/cber/rules/htm>).